SlideShare uma empresa Scribd logo
1 de 45
Quality of life  after rectal surgery Emmanuel Tiret Hôpital Saint-Antoine, AP-HP Université Pierre et Marie Curie, Paris VI
[object Object],[object Object],[object Object],[object Object],[object Object],Definition of Quality of Life
Patient diagnosed with rectal cancer ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Quality of life questionnaires Are they adapted to rectal cancer surgery? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Medical Outcomes Study  Short-Form-36 item questionnaire  MOS SF-36 General health questionnaire ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Medical Outcomes Study  Short-Form-36 item questionnaire  MOS SF-36 General health questionnaire Non specific for colorectal surgery
EORTC Quality of Life Questionnaire Core-30 item  (EORTC QLQ C-30) Generic cancer questionnaire ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
EORTC QLQ C-30 Functioning scales Physical (1-5) 1.  Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase?  2. Do you have any trouble taking a long walk?  3. Do you have any trouble taking a short walk outside of the house? 4. Do you need to stay in bed or a chair during the day?  5. Do you need help with eating, dressing, washing yourself or using the toilet?  Not at All : 1 A Little : 2  Quite a Bit : 3   Very Much : 4
EORTC QLQ C-30  Functioning Scales Role (6,7) Cognitive (20,25)   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
EORTC QLQ C-30  Functioning Scales  Emotional (21-24), Social (26,27) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
EORTC QLQ C-30  Symptom scales and/or items ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
EORTC QLQ C-30  Global quality of life ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],EORTC Quality of life Questionnaire Colorectal 38-item  (EORTC QLQ-CR-38)
Quality of life after rectal surgery ,[object Object],[object Object],[object Object],[object Object]
Straight Colo-anal Anastomosis ,[object Object],[object Object],[object Object],[object Object],[object Object]
Colo-anal Anastomosis with a Colonic J-Pouch ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Functional results at follow-up (55 months) 83 patients with colonic J-pouch  Stool frequency (per 24 hours) 2.3 ± 1.3 ,[object Object],50 (60%) ,[object Object],30 (36%) ,[object Object],3 (4%) Nocturnal defaecation 24 (29%) Urgency 16 (19%) Pad wear 38 (46%) Intestinal transit regulators 22 (26,5%) Feces-flatus discrimination 21 (25,3%) Stool fragmentation (clustering) 40 (41%) Alimentary restriction 30 (36%)
Day:1   Mon  Tue   Wed Thurs    Fri  Sat   Sun   Bowel diary Michelassi  F et al. Arch Surg 1993; 128: 889-94 Day and date Details of  bowel function Instructions:  Please fill the face of the clock at the time you went to the bathroom for one week (7 days). Fill day and date. On any day please write  (see example) B L  if you had a liquid stool,  B P  if you had a pasty stool  B F   if you had a formed stool. Also write… Sx if you were incontinent  of the entire bowel movement  Sm if you had a mild to moderate leakage in your underwear or pad E if you went to the bathroom and did not evacuate or  E D .if you had difficulty evacuating   Comments on evacuation difficulty or incomplete evacuation
Ann Surg 2007; 246: 481-90 ,[object Object],[object Object],[object Object]
J-pouch versus coloplasty and straight anastomosis Total daily bowel movemements over 24 months  J-pouch vs coloplasty : 0.03 at 4 months   0.03 at 12 months    0.007 at 24 months Ann Surg 2007; 246: 481-90
J-pouch versus coloplasty and straight anastomosis Comparison of Fecal Incontinence Severity Index (FISI) over 24 months J-pouch vs coloplasty : 0.001 at 4 months   0.04 at 24 months Ann Surg 2007; 246: 481-90
Clustering at 12 and 24 months was more often  seen in the CP group than in the J group, but  not different in the SA group and CP group Clustering at 24 months CP SA p CP J p Never 7% 16% 0.21 21% 10% <0.03 1-4 / per month 38% 37% 39% 27% >2 per week 22% 22% 20% 24% 1 or >1 per day 33% 25% 20% 39%
J-pouch versus coloplasty and straight anastomosis Comparison of Quality of Life with SF-36 Ann Surg 2007; 246: 481-90 No difference at  24 months (score SF 36) Relative insentivity of the SF-36 ??
Quality of life at  median of 13 years of 97 patients  in relation to chemoradiotherapy EORTC QLQ C-30 EORTC QLQ C-38 C Hoerske   BJS 2010; 97: 1295-03
MRC CR07/NCIC CTG C016 trial  PreopRT  25 Gy vs selective postoperative CRT 45 Gy + Fufol Baseline quality of life: no difference RJ Stephens et al.   J Clin Oncol 2010
MRC CR07/NCIC CTG C016 trial  Baseline quality of life
MRC CR07/NCIC CTG C016 trial   Bowel problems RJ Stephens et al.   J Clin Oncol 2010
MRC CR07/NCIC CTG C016 trial   Unintentional release of stools RJ Stephens et al.   J Clin Oncol 2010
MRC CR07/NCIC CTG C016 trial   Male sexual dysfunction RJ Stephens et al.   J Clin Oncol 2010
General health No difference RJ Stephens et al.   J Clin Oncol 2010
Impact of preoperative radiotherapy  for rectal cancer on Patients’ Quality of life ,[object Object],[object Object],[object Object],[object Object],[object Object]
COREAN trial: Laparoscopic versus open rectal resection EORTC QLQ-C30 scores Better physical functioning, less fatigue Lancet Oncol 2010; 1: 637-45 p<0.01 p<0.05
COREAN trial: Laparoscopic versus open rectal resection EORTC QLQ-C38 scores Fewer micturition, gastro-intestinal and defecation problems Lancet Oncol 2010; 1: 637-45 p<0.05 p<0.05 p<0.01
Quality of life with laparoscopy  and  open colorectal surgery ,[object Object],[object Object],[object Object]
APER versus Sphincter-saving procedure  EORTC QLQ C-30 function scales 212 patients  No significant difference C Schmidt. Ann Surg Oncol 2005; 12: 117-23
APER versus Sphincter-saving procedure  EORTC QLQ C-30 symptom scales 212 patients C Schmidt. Ann Surg Oncol 2005; 12: 117-23 Symptoms worse in the group of SSR
APER versus Sphincter-saving procedure  Colorectal cancer specific module scales C Schmidt. Ann Surg Oncol 2005; 12: 117-23 Significant differences
Quality of life at  median of 13 years of 97 patients  in relation to need for a colostomy/ileostomy EORTC QLQ C-30 EORTC QLQ C-38 C Hoerske   BJS 2010; 97: 1295-03
[object Object],[object Object],[object Object],Quality of life APER vs Sphincter-saving procedures Pachler J, Wille J Ø rgensenP. Cochrane review 2010
Conclusion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Do patients consider preoperative chemoradiotherapy for primary rectal cancer worthwile?  Kennedy ED, Cancer 2011 online
Do patients consider preoperative chemoradiotherapy for  primary rectal cancer worthwile?  Kennedy ED, Cancer 2011 online
Do patients consider preoperative chemoradiotherapy for  primary rectal cancer worthwile? 50 healthy well educated individuals attending screening colonoscopy Kennedy ED, Cancer 2011 online
Do patients consider preoperative chemoradiotherapy for  primary rectal cancer worthwile? Kennedy ED, Cancer 2011 online
Do patients consider preoperative chemoradiotherapy for  primary rectal cancer worthwile? 27 patients required a risk of LR≤5% (-10%)  before they would choose pre-CRT+surgery Kennedy ED, Cancer 2011 online

Mais conteúdo relacionado

Semelhante a MCC 2011 - Slide 15

Liver limited Metastatic Colorectal Cancer. Case Presentation
Liver limited Metastatic Colorectal Cancer. Case PresentationLiver limited Metastatic Colorectal Cancer. Case Presentation
Liver limited Metastatic Colorectal Cancer. Case PresentationMohamed Abdulla
 
NY Prostate Cancer Conference - M. Litwin - Session 6: Documenting outcomes w...
NY Prostate Cancer Conference - M. Litwin - Session 6: Documenting outcomes w...NY Prostate Cancer Conference - M. Litwin - Session 6: Documenting outcomes w...
NY Prostate Cancer Conference - M. Litwin - Session 6: Documenting outcomes w...European School of Oncology
 
Prasit acute abdomen
Prasit acute abdomenPrasit acute abdomen
Prasit acute abdomenAimmary
 
Acute abdomen
Acute abdomenAcute abdomen
Acute abdomentaem
 
Nonoperative care versus surgery in lumbar disc herniation with radiculopathy...
Nonoperative care versus surgery in lumbar disc herniation with radiculopathy...Nonoperative care versus surgery in lumbar disc herniation with radiculopathy...
Nonoperative care versus surgery in lumbar disc herniation with radiculopathy...Kshitij Chaudhary
 
Physical Activity and Cancer, a review of innovative current research. Dr. Ni...
Physical Activity and Cancer, a review of innovative current research. Dr. Ni...Physical Activity and Cancer, a review of innovative current research. Dr. Ni...
Physical Activity and Cancer, a review of innovative current research. Dr. Ni...Irish Cancer Society
 
URINARY TRACT INFECTIONS RISK FACTORS URINARY TRACT INFECTIONS RISK FACTORS
URINARY TRACT INFECTIONS RISK FACTORS 	 URINARY TRACT INFECTIONS RISK FACTORSURINARY TRACT INFECTIONS RISK FACTORS 	 URINARY TRACT INFECTIONS RISK FACTORS
URINARY TRACT INFECTIONS RISK FACTORS URINARY TRACT INFECTIONS RISK FACTORSMedicineAndHealth14
 
Psychosocial aspect of bariatric surgery
Psychosocial aspect of bariatric surgeryPsychosocial aspect of bariatric surgery
Psychosocial aspect of bariatric surgeryAndri Andri
 
Leukocyte, Leukocyte Subsets, and Inflammatory Cytokine Response to Resistanc...
Leukocyte, Leukocyte Subsets, and Inflammatory Cytokine Response to Resistanc...Leukocyte, Leukocyte Subsets, and Inflammatory Cytokine Response to Resistanc...
Leukocyte, Leukocyte Subsets, and Inflammatory Cytokine Response to Resistanc...Coleman Mills
 
Using Enhanced Recovery After Surgery (ERAS) to Enhance Postoperative Outcomes
Using Enhanced Recovery After Surgery (ERAS) to Enhance Postoperative OutcomesUsing Enhanced Recovery After Surgery (ERAS) to Enhance Postoperative Outcomes
Using Enhanced Recovery After Surgery (ERAS) to Enhance Postoperative OutcomesWellbe
 
Functional Digestive Disorders and the Role of Diet by Giovanni Barbara
Functional Digestive Disorders and the Role of Diet by Giovanni BarbaraFunctional Digestive Disorders and the Role of Diet by Giovanni Barbara
Functional Digestive Disorders and the Role of Diet by Giovanni BarbaraKiwifruit Symposium
 
The Importance of Staying Active after a Cancer Diagnosis | Dr Anna Campbell
The Importance of Staying Active after a Cancer Diagnosis | Dr Anna CampbellThe Importance of Staying Active after a Cancer Diagnosis | Dr Anna Campbell
The Importance of Staying Active after a Cancer Diagnosis | Dr Anna CampbellScottish Cancer Prevention Network
 
Sanis-Nutrisport 2014 Nutrizione, Integrazione e Sport
Sanis-Nutrisport 2014  Nutrizione, Integrazione e SportSanis-Nutrisport 2014  Nutrizione, Integrazione e Sport
Sanis-Nutrisport 2014 Nutrizione, Integrazione e SportRoberto Conte
 
20131013 04 林慧芬_復健與安寧緩和照護
20131013 04 林慧芬_復健與安寧緩和照護20131013 04 林慧芬_復健與安寧緩和照護
20131013 04 林慧芬_復健與安寧緩和照護Kit Leong
 

Semelhante a MCC 2011 - Slide 15 (20)

Liver limited Metastatic Colorectal Cancer. Case Presentation
Liver limited Metastatic Colorectal Cancer. Case PresentationLiver limited Metastatic Colorectal Cancer. Case Presentation
Liver limited Metastatic Colorectal Cancer. Case Presentation
 
Low Back Pain & Sciatica
Low Back Pain & Sciatica Low Back Pain & Sciatica
Low Back Pain & Sciatica
 
NY Prostate Cancer Conference - M. Litwin - Session 6: Documenting outcomes w...
NY Prostate Cancer Conference - M. Litwin - Session 6: Documenting outcomes w...NY Prostate Cancer Conference - M. Litwin - Session 6: Documenting outcomes w...
NY Prostate Cancer Conference - M. Litwin - Session 6: Documenting outcomes w...
 
CONSTIPATION PPT.DR SREEJOY PATNAIK
CONSTIPATION  PPT.DR SREEJOY PATNAIKCONSTIPATION  PPT.DR SREEJOY PATNAIK
CONSTIPATION PPT.DR SREEJOY PATNAIK
 
Cadth 2015 e3 eq5 d
Cadth 2015 e3  eq5 dCadth 2015 e3  eq5 d
Cadth 2015 e3 eq5 d
 
Prasit acute abdomen
Prasit acute abdomenPrasit acute abdomen
Prasit acute abdomen
 
Acute abdomen
Acute abdomenAcute abdomen
Acute abdomen
 
Nonoperative care versus surgery in lumbar disc herniation with radiculopathy...
Nonoperative care versus surgery in lumbar disc herniation with radiculopathy...Nonoperative care versus surgery in lumbar disc herniation with radiculopathy...
Nonoperative care versus surgery in lumbar disc herniation with radiculopathy...
 
Physical Activity and Cancer, a review of innovative current research. Dr. Ni...
Physical Activity and Cancer, a review of innovative current research. Dr. Ni...Physical Activity and Cancer, a review of innovative current research. Dr. Ni...
Physical Activity and Cancer, a review of innovative current research. Dr. Ni...
 
URINARY TRACT INFECTIONS RISK FACTORS URINARY TRACT INFECTIONS RISK FACTORS
URINARY TRACT INFECTIONS RISK FACTORS 	 URINARY TRACT INFECTIONS RISK FACTORSURINARY TRACT INFECTIONS RISK FACTORS 	 URINARY TRACT INFECTIONS RISK FACTORS
URINARY TRACT INFECTIONS RISK FACTORS URINARY TRACT INFECTIONS RISK FACTORS
 
Psychosocial aspect of bariatric surgery
Psychosocial aspect of bariatric surgeryPsychosocial aspect of bariatric surgery
Psychosocial aspect of bariatric surgery
 
Leukocyte, Leukocyte Subsets, and Inflammatory Cytokine Response to Resistanc...
Leukocyte, Leukocyte Subsets, and Inflammatory Cytokine Response to Resistanc...Leukocyte, Leukocyte Subsets, and Inflammatory Cytokine Response to Resistanc...
Leukocyte, Leukocyte Subsets, and Inflammatory Cytokine Response to Resistanc...
 
Using Enhanced Recovery After Surgery (ERAS) to Enhance Postoperative Outcomes
Using Enhanced Recovery After Surgery (ERAS) to Enhance Postoperative OutcomesUsing Enhanced Recovery After Surgery (ERAS) to Enhance Postoperative Outcomes
Using Enhanced Recovery After Surgery (ERAS) to Enhance Postoperative Outcomes
 
Sex and Cancer, Jeanne Carter, PhD
Sex and Cancer, Jeanne Carter, PhDSex and Cancer, Jeanne Carter, PhD
Sex and Cancer, Jeanne Carter, PhD
 
D de Jong, Prostate cancer brachytherapy
D de Jong, Prostate cancer brachytherapyD de Jong, Prostate cancer brachytherapy
D de Jong, Prostate cancer brachytherapy
 
Functional Digestive Disorders and the Role of Diet by Giovanni Barbara
Functional Digestive Disorders and the Role of Diet by Giovanni BarbaraFunctional Digestive Disorders and the Role of Diet by Giovanni Barbara
Functional Digestive Disorders and the Role of Diet by Giovanni Barbara
 
The Importance of Staying Active after a Cancer Diagnosis | Dr Anna Campbell
The Importance of Staying Active after a Cancer Diagnosis | Dr Anna CampbellThe Importance of Staying Active after a Cancer Diagnosis | Dr Anna Campbell
The Importance of Staying Active after a Cancer Diagnosis | Dr Anna Campbell
 
Healthy aging
Healthy agingHealthy aging
Healthy aging
 
Sanis-Nutrisport 2014 Nutrizione, Integrazione e Sport
Sanis-Nutrisport 2014  Nutrizione, Integrazione e SportSanis-Nutrisport 2014  Nutrizione, Integrazione e Sport
Sanis-Nutrisport 2014 Nutrizione, Integrazione e Sport
 
20131013 04 林慧芬_復健與安寧緩和照護
20131013 04 林慧芬_復健與安寧緩和照護20131013 04 林慧芬_復健與安寧緩和照護
20131013 04 林慧芬_復健與安寧緩和照護
 

Mais de European School of Oncology

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasEuropean School of Oncology
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineEuropean School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerEuropean School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artEuropean School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 

Mais de European School of Oncology (20)

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 

MCC 2011 - Slide 15

  • 1. Quality of life after rectal surgery Emmanuel Tiret Hôpital Saint-Antoine, AP-HP Université Pierre et Marie Curie, Paris VI
  • 2.
  • 3.
  • 4.
  • 5.
  • 6. Medical Outcomes Study Short-Form-36 item questionnaire MOS SF-36 General health questionnaire Non specific for colorectal surgery
  • 7.
  • 8. EORTC QLQ C-30 Functioning scales Physical (1-5) 1. Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase? 2. Do you have any trouble taking a long walk? 3. Do you have any trouble taking a short walk outside of the house? 4. Do you need to stay in bed or a chair during the day? 5. Do you need help with eating, dressing, washing yourself or using the toilet? Not at All : 1 A Little : 2 Quite a Bit : 3 Very Much : 4
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18. Day:1   Mon Tue   Wed Thurs   Fri Sat   Sun   Bowel diary Michelassi F et al. Arch Surg 1993; 128: 889-94 Day and date Details of bowel function Instructions: Please fill the face of the clock at the time you went to the bathroom for one week (7 days). Fill day and date. On any day please write (see example) B L if you had a liquid stool, B P if you had a pasty stool B F if you had a formed stool. Also write… Sx if you were incontinent of the entire bowel movement Sm if you had a mild to moderate leakage in your underwear or pad E if you went to the bathroom and did not evacuate or E D .if you had difficulty evacuating   Comments on evacuation difficulty or incomplete evacuation
  • 19.
  • 20. J-pouch versus coloplasty and straight anastomosis Total daily bowel movemements over 24 months J-pouch vs coloplasty : 0.03 at 4 months 0.03 at 12 months 0.007 at 24 months Ann Surg 2007; 246: 481-90
  • 21. J-pouch versus coloplasty and straight anastomosis Comparison of Fecal Incontinence Severity Index (FISI) over 24 months J-pouch vs coloplasty : 0.001 at 4 months 0.04 at 24 months Ann Surg 2007; 246: 481-90
  • 22. Clustering at 12 and 24 months was more often seen in the CP group than in the J group, but not different in the SA group and CP group Clustering at 24 months CP SA p CP J p Never 7% 16% 0.21 21% 10% <0.03 1-4 / per month 38% 37% 39% 27% >2 per week 22% 22% 20% 24% 1 or >1 per day 33% 25% 20% 39%
  • 23. J-pouch versus coloplasty and straight anastomosis Comparison of Quality of Life with SF-36 Ann Surg 2007; 246: 481-90 No difference at 24 months (score SF 36) Relative insentivity of the SF-36 ??
  • 24. Quality of life at median of 13 years of 97 patients in relation to chemoradiotherapy EORTC QLQ C-30 EORTC QLQ C-38 C Hoerske BJS 2010; 97: 1295-03
  • 25. MRC CR07/NCIC CTG C016 trial PreopRT 25 Gy vs selective postoperative CRT 45 Gy + Fufol Baseline quality of life: no difference RJ Stephens et al. J Clin Oncol 2010
  • 26. MRC CR07/NCIC CTG C016 trial Baseline quality of life
  • 27. MRC CR07/NCIC CTG C016 trial Bowel problems RJ Stephens et al. J Clin Oncol 2010
  • 28. MRC CR07/NCIC CTG C016 trial Unintentional release of stools RJ Stephens et al. J Clin Oncol 2010
  • 29. MRC CR07/NCIC CTG C016 trial Male sexual dysfunction RJ Stephens et al. J Clin Oncol 2010
  • 30. General health No difference RJ Stephens et al. J Clin Oncol 2010
  • 31.
  • 32. COREAN trial: Laparoscopic versus open rectal resection EORTC QLQ-C30 scores Better physical functioning, less fatigue Lancet Oncol 2010; 1: 637-45 p<0.01 p<0.05
  • 33. COREAN trial: Laparoscopic versus open rectal resection EORTC QLQ-C38 scores Fewer micturition, gastro-intestinal and defecation problems Lancet Oncol 2010; 1: 637-45 p<0.05 p<0.05 p<0.01
  • 34.
  • 35. APER versus Sphincter-saving procedure EORTC QLQ C-30 function scales 212 patients No significant difference C Schmidt. Ann Surg Oncol 2005; 12: 117-23
  • 36. APER versus Sphincter-saving procedure EORTC QLQ C-30 symptom scales 212 patients C Schmidt. Ann Surg Oncol 2005; 12: 117-23 Symptoms worse in the group of SSR
  • 37. APER versus Sphincter-saving procedure Colorectal cancer specific module scales C Schmidt. Ann Surg Oncol 2005; 12: 117-23 Significant differences
  • 38. Quality of life at median of 13 years of 97 patients in relation to need for a colostomy/ileostomy EORTC QLQ C-30 EORTC QLQ C-38 C Hoerske BJS 2010; 97: 1295-03
  • 39.
  • 40.
  • 41. Do patients consider preoperative chemoradiotherapy for primary rectal cancer worthwile? Kennedy ED, Cancer 2011 online
  • 42. Do patients consider preoperative chemoradiotherapy for primary rectal cancer worthwile? Kennedy ED, Cancer 2011 online
  • 43. Do patients consider preoperative chemoradiotherapy for primary rectal cancer worthwile? 50 healthy well educated individuals attending screening colonoscopy Kennedy ED, Cancer 2011 online
  • 44. Do patients consider preoperative chemoradiotherapy for primary rectal cancer worthwile? Kennedy ED, Cancer 2011 online
  • 45. Do patients consider preoperative chemoradiotherapy for primary rectal cancer worthwile? 27 patients required a risk of LR≤5% (-10%) before they would choose pre-CRT+surgery Kennedy ED, Cancer 2011 online